Led · Series A · May 2026

Gilgamesh Pharmaceuticals pursues discovery and development of improved neuropsychiatric drugs, using a platform that combines neural-circuit translational methods with AI and machine learning to optimize safety, efficacy and dosing. Its pipeline includes the ibogaine-analog GM-3009 (supported by a $14 million NIDA grant), the oral NMDAR antagonist GM-1020 (completed Phase 1 SAD/MAD and progressed into Phase 2), non-hallucinogenic neuroplasticity candidates now in IND-enabling stages, and projects targeting M1/M4 receptors. In August 2025 the company completed a strategic divestiture of clinical-stage candidate GM-2505 to AbbVie for up to $1.2 billion, and it has a separate AbbVie collaboration that included a $65 million upfront payment and up to $1.95 billion in option/ milestone payments plus royalties. The company assembled a leadership team with extensive CNS drug-development experience and intends to use recent financing to fund clinical and preclinical programs and continued discovery efforts. Gilgamesh was founded in 2019 by Jonathan Sporn and Andrew Kruegel.

Participated · Series A · Nov 2025

Mountain View-based NextSense is developing Smartbuds, the first fully wireless consumer earbuds equipped with clinically accurate in-ear EEG sensors. The device pairs continuous brain-wave monitoring with adaptive algorithms that trigger soundscapes proven to deepen slow-wave sleep by up to 50 % among early users. Beyond sleep, upcoming Relax and Focus modes will deliver brain-responsive audio that adjusts in real time to calmer or more attentive mental states. Smartbuds are scheduled to ship in Q4 2025 and are currently available for pre-order. The company plans to expand into research collaborations with universities and pharmaceutical companies and to introduce medical-grade applications in 2027. An oversubscribed $16 million Series A now funds commercialization, additional product features, and clinical validation efforts. Investors view the platform as a gateway to democratizing brain health by moving wearables from passive tracking to proactive improvement.

Participated · Series A · Oct 2025

Ampa develops the Ampa One, an FDA-cleared, portable transcranial magnetic stimulation (TMS) system designed for simplicity and scalability. The company says the device fits in the trunk of a car, costs $3,000 per month, can be operated after a few hours of training, and features a lightweight hand-holdable coil, camera-guided targeting, and pre-printed neuronavigation caps. Ampa reports the Ampa One is already in use at clinics across more than 30 U.S. states and that demand has doubled every quarter. The company secured regulatory approval in Israel and plans commercial launch overseas. Leadership cited in the announcement includes co-founder Jonathan Downar, MD, PhD, and CEO Don Vaughn, PhD. Ampa positions the product as a lower-cost, higher-throughput option for clinics and is using recent financing to accelerate rollout and meet accelerating demand.

Participated · Seed · Oct 2024

Holobiome has built the Microbiome Vault, a diverse collection of human gut bacteria, and performs target-directed screening to map how the microbiome influences health. The company uses large datasets from these screens to inform development of novel consumer products and drug candidates. Its initial focus is on the gut–brain axis, with a lead program that is a next‑generation probiotic targeting biology relevant to depression. Holobiome advances additional programs via partnerships with major consumer, food, and pharmaceutical partners in areas including stress and pain. The company was launched in 2018 and is headquartered in Boston. Holobiome has secured substantial non-dilutive funding (including NIH and TRISH grants) and recently closed an institutional seed round to support clinical advancement and platform expansion.

Participated · Series A · Jun 2024

Hoodie Analytics is a Chicago-based cannabis data and technology company that offers a market insights and product data management platform. Led by CEO Wes Shepherd, the platform tracks daily movements of the cannabis market and gives users access to people, processes, and data aimed at building winning brands. The company recently launched its new platform and plans to use the financing to accelerate market expansion. Hoodie strengthened its leadership and governance with the appointment of David Navama and the addition of Timur Sultanov to the board, alongside observers Andy Sturner and John Campbell. The business is focused on scaling its product and commercial reach within the cannabis sector. Hoodie Analytics operates a cannabis data and technology platform that tracks over 3.5 million daily unique offers across more than 8,000 dispensaries in the U.S. and Canada, capturing pricing, promotion, stocking status, distribution, and share-of-shelf metrics. It delivers next-day insights, enabling businesses to access market trends and data within hours. The company combines massive-volume data processing with application development and an easy-to-use interface intended for roles from brand salespeople to dispensary inventory managers. Hoodie aims to track every product in every dispensary every day and to build a product graph that connects industry participants. The executive team includes alumni from IRI, Nielsen, NPD, and Numerator. Hoodie says the recent fundraising will allow it to massively scale product and sales efforts and has added strategic advisory board members to support growth.